RT Journal Article
T1 Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy.
A1 Parra-Millán, Raquel
A1 Jiménez-Mejías, Manuel E
A1 Ayerbe-Algaba, Rafael
A1 Domínguez-Herrera, Juan
A1 Díaz, Caridad
A1 Pérez Del Palacio, José
A1 Pachón, Jerónimo
A1 Smani, Younes
K1 Combined antimicrobial treatment
K1 Immune response
K1 Lisofosfatidilcolina
K1 Lysophosphatidylcholine
K1 Modelo de sepsis peritoneal, Modelo de neumonía
K1 Peritoneal sepsis model
K1 Pneumonia model
K1 Pseudomonas aeruginosa
K1 Respuesta inmunitaria
K1 Tratamiento antimicrobiano combinado
AB Immune response stimulation may be an adjuvant to antimicrobial treatment. Here, we evaluated the impact of immune response modification by lysophosphatidylcholine (LPC), combined with imipenem or ceftazidime, in murine models of peritoneal sepsis (PS) and pneumonia induced by Pseudomonas aeruginosa. The imipenem and ceftazidime-susceptible strain (Pa39) and imipenem and ceftazidime-resistant strain (Pa238) were used. Ceftazidime pharmacokinetic and pharmacodynamic parameters were determined. The therapeutic efficacy and TNF-α and IL-10 levels were determined in murine models of PS and pneumonia induced by Pa39 and Pa238 and treated with LPC, imipenem or ceftazidime, alone or in combination. In the PS model, LPC+ceftazidime reduced spleen and lung Pa238 concentrations (-3.45 and -3.56log10CFU/g; P0.05). In the pneumonia model, LPC+ceftazidime or LPC+imipenem reduced the lung Pa238 concentrations (-2.37log10CFU/g, P=0.1, or -1.35log10CFU/g, P=0.75). For Pa39, no statistically significant difference was observed in the PS and pneumonia models between combined therapy and monotherapy. Moreover, LPC+imipenem and LPC+ceftazidime significantly decreased and increased the TNF-α and IL-10 levels, respectively, in comparison with the untreated controls and monotherapies. These results demonstrate the impact of immune response modification by LPC plus antibiotics on the prognosis of infections induced by ceftazidime-resistant P. aeruginosa.
YR 2020
FD 2020-07-13
LK http://hdl.handle.net/10668/22165
UL http://hdl.handle.net/10668/22165
LA en
LA es
DS RISalud
RD Apr 20, 2025